AngioDynamics Q1 2025 Adj. EPS $(0.11) Beats $(0.15) Estimate, Sales $67.491M Miss $67.933M Estimate
Portfolio Pulse from Benzinga Newsdesk
AngioDynamics reported its Q1 2025 financial results, with an adjusted EPS of $(0.11), beating the estimate of $(0.15). However, sales were $67.491 million, slightly missing the $67.933 million estimate.
October 03, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AngioDynamics' Q1 2025 adjusted EPS of $(0.11) exceeded expectations, but sales of $67.491 million fell short of estimates. This mixed result may lead to a neutral to slightly positive short-term impact on the stock.
The better-than-expected EPS suggests cost management or operational efficiency, which is positive. However, the sales miss indicates potential challenges in revenue generation. The mixed results may balance each other out, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100